Arbutus Biopharma: Promising Clinical Trials and Patent Litigation Could Drive Investor Interest in 2024
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) this week outlined its business outlook for 2024, highlighting upcoming clinical milestones and a robust financial position that could make it an …
Arbutus Biopharma: Promising Clinical Trials and Patent Litigation Could Drive Investor Interest in 2024 Read More